Developer docs
API playgroundTry for free, no card

Search company profiles

Saniona

Full company profile

uuid000418d

Namestring
Saniona
Legal namestring
Saniona AB (publ)
Websiteurl
saniona.com
Company typeenum
Public
Founded yearint
2011
Descriptiontext

Saniona AB (publ) is a clinical-stage biopharmaceutical company founded in 2011 and listed on Nasdaq Stockholm Small Cap under the ticker SANION, with operating headquarters in Glostrup, Denmark. The company is a pioneer in ion channel research and operates a proprietary drug discovery platform that has generated a library of more than 20,000 proprietary small molecules targeting various ion channels. Saniona focuses on neurological, psychiatric, and rare disease indications with high unmet medical need, including severe pediatric epilepsies (SAN2668, SAN2219, SAN711, SAN2355), major depressive disorder (SAN2465), inflammatory bowel disease and fibrotic diseases (SAN903), and rare obesity disorders (Tesomet for hypothalamic obesity and Prader-Willi syndrome, tesofensin partnered with Medix for Mexico/Argentina).

Saniona's business model is a capital-efficient partnered development model. The company discovers and develops pre-clinical and early-clinical candidates internally using its ion channel platform, then out-licenses global or regional development and commercialization rights to pharmaceutical partners who fund further clinical trials, regulatory submissions, and commercialization. Revenue is generated from licensing upfront payments, development and regulatory milestone payments, and royalties, supplemented by non-dilutive funding from research collaborations with Boehringer Ingelheim, AstronauTx, and Cephagenix. Notable commercial partnerships include Jazz Pharmaceuticals (global rights to SAN2355, August 2025 deal potentially worth over $1 billion), Acadia Pharmaceuticals (global rights to ACP-711 for essential tremor), and Medix (tesofensin for obesity in Mexico and Argentina, with a positive COFEPRIS opinion in February 2023). The company operates with 11-50 employees and has no approved products on the market.

Short descriptiontext

Saniona is a clinical-stage biopharmaceutical company pioneering ion channel drug discovery, with a proprietary library of 20,000+ molecules targeting neurological, psychiatric, and rare diseases. It licenses pipeline assets to pharmaceutical partners including Jazz, Acadia, and Medix for global development and commercialization.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersGlostrup, Denmark
HQ citystring
Glostrup
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ion channel drug discovery, clinical-stage biopharmaceuticals, neurological disease therapeutics, rare disease drug development, epilepsy treatment pipeline
Industry4 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
Product category
Clinical-stage biopharmaceuticals (ion channel therapeutics)
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and milestone payments
TypeLicensing Royalties
Description

Saniona generates revenue through upfront payments, development milestones, regulatory milestones, and commercial royalties from licensing agreements with pharmaceutical partners who acquire global rights to its pipeline candidates (e.g., Jazz Pharmaceuticals for SAN2355, Acadia Pharmaceuticals for ACP-711, Medix for tesofensin in Mexico/Argentina). The Jazz deal for SAN2355 is described as potentially over one billion dollars.

thepharmaletter.com
2Research and development partnerships
TypeProfessional Services
Description

Saniona participates in research collaborations with pharmaceutical companies (Boehringer Ingelheim, AstronauTx, Cephagenix) that provide funding for early-stage discovery and platform validation. These partnerships contribute non-dilutive capital.

saniona.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Saniona is a clinical-stage biopharmaceutical company that discovers and develops novel treatments for neurological, psychiatric, metabolic, and inflammatory diseases by leveraging a proprietary ion channel drug discovery platform with a library of more than 20,000 proprietary molecules. Its pipeline includes clinical and preclinical candidates for epilepsy (SAN2668, SAN2219, SAN711, SAN2355), depression (SAN2465), inflammatory bowel disease (SAN903), and obesity-related rare disorders (Tesofensin, Tesomet), with most late-stage and commercial rights out-licensed to pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Tesofensin demonstrated approximately 10% or greater weight loss at 24 weeks at the expected recommended dose of 0.50 mg/day in Phase 2 clinical studies, comparable to leading GLP-1 analogs. Unlike GLP-1 analogs, tesofensin is provided as a tablet without requiring titration.
+2 more records
Product overview1 text field

Saniona is a clinical-stage biopharmaceutical company and pioneer in ion channel research, advancing multiple potential new medicines through clinical trials. The company's product portfolio centers on its proprietary ion channel drug discovery platform, which has generated a library of more than 20,000 proprietary molecules targeting various ion channels. Saniona's internal epilepsy pipeline includes SAN2668 (leading clinical candidate for severe pediatric epilepsies, moving toward Phase 1 in 2026), SAN711 (ready for Phase 2 for absences), and SAN2219 (preclinical for acute repetitive epileptic seizures). Beyond epilepsy, the company has partnered programs including Tesofensin (partnered with Medix for obesity) and Tesomet (for hypothalamic obesity and Prader-Willi syndrome), as well as SAN903 (for inflammatory bowel disease) and SAN2465 (for severe depression). SAN2355 was licensed to Jazz Pharmaceuticals for global development in epilepsy.

Product and service9 records
1SAN2668
CategoryClinical drug candidate
Description

Subtype-selective GABAA positive allosteric modulator (PAM) designed with selective pharmacology targeting relevant GABAA receptor subtypes involved in seizure control; Saniona's leading clinical candidate for treatment of severe pediatric epilepsies including developmental and epileptic encephalopathies (DEEs).

2SAN2219
CategoryClinical drug candidate
Description

Subtype-selective positive allosteric modulator of GABAA alpha2, alpha3, and alpha5 receptors designed to induce robust anti-seizure effects for acute repetitive epileptic seizures by broadly dampening excessive neuronal activation without the sedating effects of non-selective benzodiazepines.

3SAN711
CategoryClinical drug candidate
Description

Saniona's most advanced patented ion channel modulator being developed for the treatment of absence seizures (a form of epileptic seizures); Phase 1 study on healthy volunteers reported positive results in July 2022 and the candidate is ready for Phase 2 clinical studies.

4SAN2355
CategoryPreclinical drug candidate (licensed)
Description

Preclinical Kv7.2/Kv7.3 ion channel activator being investigated for epilepsy and other potential indications; development and commercialization rights licensed exclusively worldwide to Jazz Pharmaceuticals following an August 2025 global licensing agreement.

5Tesofensin
CategoryClinical drug candidate (partnered)
Description

Unique triple monoamine reuptake inhibitor modulating dopamine, serotonin, and norepinephrine to regulate appetite, food-seeking behavior, and metabolism; partnered with Medix for obesity treatment in Mexico and Argentina where a marketing authorization application is under review, demonstrated approximately 10% or greater weight loss at 24 weeks at 0.50 mg/day in Phase 2 studies.

6Tesomet
CategoryClinical drug candidate
Description

Fixed-dose combination of tesofensine (triple monoamine reuptake inhibitor) and metoprolol (selective beta-1 blocker) being developed for hypothalamic obesity and Prader-Willi syndrome; Phase 2b studies voluntarily paused for financial reasons unrelated to safety or efficacy.

7SAN903
CategoryPreclinical drug candidate
Description

Potential first-in-class inhibitor of the calcium-activated potassium channel KCa3.1 for inflammatory and fibrotic diseases; lead indication is inflammatory bowel disease (IBD) and the candidate is ready for Phase 1 clinical trials.

8SAN2465
CategoryPreclinical drug candidate
Description

Highly potent and selective negative allosteric modulator (NAM) of GABAA alpha5-containing receptors in development as a rapid-acting antidepressant for major depressive disorder with a pharmacological profile distinct from conventional antidepressants, NMDA antagonists, and psychedelic investigational drugs; moving toward Phase 1 studies in 2026.

9Ion Channel Drug Discovery Platform
CategoryTechnology platform
Description

Proprietary drug discovery engine generating a library of more than 20,000 proprietary molecules targeting various ion channels, used to design highly specific ion channel modulators and to support both internal pipeline development and partnered research collaborations with pharmaceutical companies.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-21
Description

Jazz Pharmaceuticals and Saniona entered into a global license agreement granting Jazz exclusive worldwide rights to develop SAN2355, a pre-clinical Kv7.2/Kv7.3 activator being investigated for epilepsy and other potential indications. Jazz will lead and fund all further development, regulatory submissions, and global commercialization activities under the potentially over billion-dollar deal. Saniona's shares surged 58% to 12.92 kroner following the announcement.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Acadia Pharmaceuticals holds global rights to ACP-711 (a Saniona-derived asset) for essential tremor. This partnership represents an additional validation of Saniona's ion channel drug discovery platform.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Medix holds rights to tesofensin for obesity in Mexico and Argentina. Saniona's collaboration partner Medix completed a Phase 3 program for tesofensin in obesity and submitted a New Drug Application to COFEPRIS (Mexican regulatory authority). In February 2023, COFEPRIS technical committee issued a positive opinion on tesofensin as a treatment for obesity.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

UCB is a large global biopharmaceutical company with a major franchise in epilepsy (e.g., Vimpat, Briviact, Keppra) and a growing presence in rare diseases through its acquisition of Zogenix. Its deep epilepsy portfolio makes it a relevant broad incumbent comparable to Saniona's CNS pipeline.

TypeDirect peer
Description

Axsome Therapeutics is a CNS-focused biopharmaceutical company with approved products for major depressive disorder and migraine. Its rapid-acting antidepressant franchise and CNS pipeline positioning make it a direct comparable to Saniona's SAN2465 and broader CNS strategy.

TypeDirect peer
Description

Marinus Pharmaceuticals is a clinical-stage company developing GABAA receptor modulators for seizure disorders including status epilepticus and rare epilepsies. Its mechanism of action and patient focus on rare pediatric epilepsies directly overlaps with Saniona's epilepsy franchise.

TypeDirect peer
Description

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ion channel drug discovery for neurological disorders, including epilepsy. Its pipeline of Kv7 and other ion channel modulators directly parallels Saniona's ion channel platform, making it the closest comparable in mechanism and therapeutic focus.

TypeDirect peer
Description

Sage Therapeutics is a CNS-focused biopharmaceutical company with approved products in depression (Zurzuvae) and historically in epilepsy. Its GABAA receptor modulator franchise directly competes with Saniona's SAN2219 and SAN2668 programs in CNS indications.

TypeDirect peer
Description

Praxis Precision Medicines is a clinical-stage company developing therapies for CNS disorders including epilepsy and rare pediatric neurological conditions. Its focus on treatment-resistant epilepsies and rare CNS indications directly overlaps Saniona's SAN2668 and SAN2219 programs.

TypeEmerging player
Description

Longboard Pharmaceuticals is a clinical-stage company developing CNS therapies, including a 5-HT2C receptor agonist for rare epilepsies. Its smaller scale and CNS focus make it an emerging comparable to Saniona's pediatric epilepsy strategy.

TypeEmerging player
Description

Engage Therapeutics (acquired by UCB in 2020) developed a Staccato alprazolam therapy for acute repetitive seizures — directly overlapping with Saniona's SAN2219 program. As a recently validated target in acute seizure treatment, it represents an emerging comparable for Saniona's acute repetitive seizure strategy.

TypeBroad incumbent
Description

Jazz Pharmaceuticals is a large global biopharmaceutical company with deep CNS and epilepsy franchises (e.g., Epidiolex, Xywav). It is Saniona's licensee for SAN2355 and represents the type of established CNS player Saniona's partnered model is designed to access for late-stage development.

TypeBroad incumbent
Description

Acadia Pharmaceuticals is a CNS-focused biopharmaceutical company with an approved product for Parkinson's disease psychosis and a pipeline in essential tremor and other CNS indications. It licenses ACP-711 from Saniona for essential tremor, providing direct platform validation and representing a broader CNS incumbent comparable.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Saniona

Clinical-stage biopharmaceuticals (ion channel therapeutics)saniona.com

Saniona is a clinical-stage biopharmaceutical company pioneering ion channel drug discovery, with a proprietary library of 20,000+ molecules targeting neurological, psychiatric, and rare diseases. It licenses pipeline assets to pharmaceutical partners including Jazz, Acadia, and Medix for global development and commercialization.

What Saniona does

Saniona AB (publ) is a clinical-stage biopharmaceutical company founded in 2011 and listed on Nasdaq Stockholm Small Cap under the ticker SANION, with operating headquarters in Glostrup, Denmark. The company is a pioneer in ion channel research and operates a proprietary drug discovery platform that has generated a library of more than 20,000 proprietary small molecules targeting various ion channels. Saniona focuses on neurological, psychiatric, and rare disease indications with high unmet medical need, including severe pediatric epilepsies (SAN2668, SAN2219, SAN711, SAN2355), major depressive disorder (SAN2465), inflammatory bowel disease and fibrotic diseases (SAN903), and rare obesity disorders (Tesomet for hypothalamic obesity and Prader-Willi syndrome, tesofensin partnered with Medix for Mexico/Argentina).

Saniona's business model is a capital-efficient partnered development model. The company discovers and develops pre-clinical and early-clinical candidates internally using its ion channel platform, then out-licenses global or regional development and commercialization rights to pharmaceutical partners who fund further clinical trials, regulatory submissions, and commercialization. Revenue is generated from licensing upfront payments, development and regulatory milestone payments, and royalties, supplemented by non-dilutive funding from research collaborations with Boehringer Ingelheim, AstronauTx, and Cephagenix. Notable commercial partnerships include Jazz Pharmaceuticals (global rights to SAN2355, August 2025 deal potentially worth over $1 billion), Acadia Pharmaceuticals (global rights to ACP-711 for essential tremor), and Medix (tesofensin for obesity in Mexico and Argentina, with a positive COFEPRIS opinion in February 2023). The company operates with 11-50 employees and has no approved products on the market.

Saniona firmographics

Firmographics
Name
Saniona
Legal name
Saniona AB (publ)
Website
https://saniona.com
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
51–100 employees
Short description
Saniona is a clinical-stage biopharmaceutical company pioneering ion channel drug discovery, with a proprietary library of 20,000+ molecules targeting neurological, psychiatric, and rare diseases. It licenses pipeline assets to pharmaceutical partners including Jazz, Acadia, and Medix for global development and commercialization.
Ownership category
akta.pro rank

Saniona industry classification

Industry
Product category
Clinical-stage biopharmaceuticals (ion channel therapeutics)
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals

Keywords

  • Ion channel drug discovery
  • Clinical-stage biopharmaceuticals
  • Neurological disease therapeutics
  • Rare disease drug development
  • Epilepsy treatment pipeline

Where Saniona is headquartered

Location

Headquarters

HQ city
Glostrup
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

Saniona business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing and milestone payments: Saniona generates revenue through upfront payments, development milestones, regulatory milestones, and commercial royalties from licensing agreements with pharmaceutical partners who acquire global rights to its pipeline candidates (e.g., Jazz Pharmaceuticals for SAN2355, Acadia Pharmaceuticals for ACP-711, Medix for tesofensin in Mexico/Argentina). The Jazz deal for SAN2355 is described as potentially over one billion dollars.
  2. Research and development partnerships: Saniona participates in research collaborations with pharmaceutical companies (Boehringer Ingelheim, AstronauTx, Cephagenix) that provide funding for early-stage discovery and platform validation. These partnerships contribute non-dilutive capital.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Saniona product offering

Product offering

Core offering

Saniona is a clinical-stage biopharmaceutical company that discovers and develops novel treatments for neurological, psychiatric, metabolic, and inflammatory diseases by leveraging a proprietary ion channel drug discovery platform with a library of more than 20,000 proprietary molecules. Its pipeline includes clinical and preclinical candidates for epilepsy (SAN2668, SAN2219, SAN711, SAN2355), depression (SAN2465), inflammatory bowel disease (SAN903), and obesity-related rare disorders (Tesofensin, Tesomet), with most late-stage and commercial rights out-licensed to pharmaceutical partners.

Product overview

Saniona is a clinical-stage biopharmaceutical company and pioneer in ion channel research, advancing multiple potential new medicines through clinical trials. The company's product portfolio centers on its proprietary ion channel drug discovery platform, which has generated a library of more than 20,000 proprietary molecules targeting various ion channels. Saniona's internal epilepsy pipeline includes SAN2668 (leading clinical candidate for severe pediatric epilepsies, moving toward Phase 1 in 2026), SAN711 (ready for Phase 2 for absences), and SAN2219 (preclinical for acute repetitive epileptic seizures). Beyond epilepsy, the company has partnered programs including Tesofensin (partnered with Medix for obesity) and Tesomet (for hypothalamic obesity and Prader-Willi syndrome), as well as SAN903 (for inflammatory bowel disease) and SAN2465 (for severe depression). SAN2355 was licensed to Jazz Pharmaceuticals for global development in epilepsy.

Differentiator

Problem solved

Functional benefit

Products and services

  • SAN2668 Subtype-selective GABAA positive allosteric modulator (PAM) designed with selective pharmacology targeting relevant GABAA receptor subtypes involved in seizure control; Saniona's leading clinical candidate for treatment of severe pediatric epilepsies including developmental and epileptic encephalopathies (DEEs).
  • SAN2219 Subtype-selective positive allosteric modulator of GABAA alpha2, alpha3, and alpha5 receptors designed to induce robust anti-seizure effects for acute repetitive epileptic seizures by broadly dampening excessive neuronal activation without the sedating effects of non-selective benzodiazepines.
  • SAN711 Saniona's most advanced patented ion channel modulator being developed for the treatment of absence seizures (a form of epileptic seizures); Phase 1 study on healthy volunteers reported positive results in July 2022 and the candidate is ready for Phase 2 clinical studies.
  • SAN2355 Preclinical Kv7.2/Kv7.3 ion channel activator being investigated for epilepsy and other potential indications; development and commercialization rights licensed exclusively worldwide to Jazz Pharmaceuticals following an August 2025 global licensing agreement.
  • Tesofensin Unique triple monoamine reuptake inhibitor modulating dopamine, serotonin, and norepinephrine to regulate appetite, food-seeking behavior, and metabolism; partnered with Medix for obesity treatment in Mexico and Argentina where a marketing authorization application is under review, demonstrated approximately 10% or greater weight loss at 24 weeks at 0.50 mg/day in Phase 2 studies.
  • Tesomet Fixed-dose combination of tesofensine (triple monoamine reuptake inhibitor) and metoprolol (selective beta-1 blocker) being developed for hypothalamic obesity and Prader-Willi syndrome; Phase 2b studies voluntarily paused for financial reasons unrelated to safety or efficacy.
  • SAN903 Potential first-in-class inhibitor of the calcium-activated potassium channel KCa3.1 for inflammatory and fibrotic diseases; lead indication is inflammatory bowel disease (IBD) and the candidate is ready for Phase 1 clinical trials.
  • SAN2465 Highly potent and selective negative allosteric modulator (NAM) of GABAA alpha5-containing receptors in development as a rapid-acting antidepressant for major depressive disorder with a pharmacological profile distinct from conventional antidepressants, NMDA antagonists, and psychedelic investigational drugs; moving toward Phase 1 studies in 2026.
  • Ion Channel Drug Discovery Platform Proprietary drug discovery engine generating a library of more than 20,000 proprietary molecules targeting various ion channels, used to design highly specific ion channel modulators and to support both internal pipeline development and partnered research collaborations with pharmaceutical companies.

Quantifiable outcome

  • Tesofensin demonstrated approximately 10% or greater weight loss at 24 weeks at the expected recommended dose of 0.50 mg/day in Phase 2 clinical studies, comparable to leading GLP-1 analogs. Unlike GLP-1 analogs, tesofensin is provided as a tablet without requiring titration.
  • +2 more outcomes

Companies that use Saniona

Customer profile

Segments6 records

Ideal customer profiles2 records

Saniona technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Saniona partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Jazz PharmaceuticalscoreStrategic or Co-development Partner · 21 August 2025Jazz Pharmaceuticals and Saniona entered into a global license agreement granting Jazz exclusive worldwide rights to develop SAN2355, a pre-clinical Kv7.2/Kv7.3 activator being investigated for epilepsy and other potential indications. Jazz will lead and fund all further development, regulatory submissions, and global commercialization activities under the potentially over billion-dollar deal. Saniona's shares surged 58% to 12.92 kroner following the announcement.
  • Acadia PharmaceuticalscoreStrategic or Co-development PartnerAcadia Pharmaceuticals holds global rights to ACP-711 (a Saniona-derived asset) for essential tremor. This partnership represents an additional validation of Saniona's ion channel drug discovery platform.
  • MedixcoreStrategic or Co-development PartnerMedix holds rights to tesofensin for obesity in Mexico and Argentina. Saniona's collaboration partner Medix completed a Phase 3 program for tesofensin in obesity and submitted a New Drug Application to COFEPRIS (Mexican regulatory authority). In February 2023, COFEPRIS technical committee issued a positive opinion on tesofensin as a treatment for obesity.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Saniona competitors and assessment

Company assessment

Broad incumbents

  • UCB: UCB is a large global biopharmaceutical company with a major franchise in epilepsy (e.g., Vimpat, Briviact, Keppra) and a growing presence in rare diseases through its acquisition of Zogenix. Its deep epilepsy portfolio makes it a relevant broad incumbent comparable to Saniona's CNS pipeline.
  • Jazz Pharmaceuticals: Jazz Pharmaceuticals is a large global biopharmaceutical company with deep CNS and epilepsy franchises (e.g., Epidiolex, Xywav). It is Saniona's licensee for SAN2355 and represents the type of established CNS player Saniona's partnered model is designed to access for late-stage development.
  • Acadia Pharmaceuticals: Acadia Pharmaceuticals is a CNS-focused biopharmaceutical company with an approved product for Parkinson's disease psychosis and a pipeline in essential tremor and other CNS indications. It licenses ACP-711 from Saniona for essential tremor, providing direct platform validation and representing a broader CNS incumbent comparable.

Direct peers

  • Axsome Therapeutics: Axsome Therapeutics is a CNS-focused biopharmaceutical company with approved products for major depressive disorder and migraine. Its rapid-acting antidepressant franchise and CNS pipeline positioning make it a direct comparable to Saniona's SAN2465 and broader CNS strategy.
  • Marinus Pharmaceuticals: Marinus Pharmaceuticals is a clinical-stage company developing GABAA receptor modulators for seizure disorders including status epilepticus and rare epilepsies. Its mechanism of action and patient focus on rare pediatric epilepsies directly overlaps with Saniona's epilepsy franchise.
  • Xenon Pharmaceuticals: Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ion channel drug discovery for neurological disorders, including epilepsy. Its pipeline of Kv7 and other ion channel modulators directly parallels Saniona's ion channel platform, making it the closest comparable in mechanism and therapeutic focus.
  • Sage Therapeutics: Sage Therapeutics is a CNS-focused biopharmaceutical company with approved products in depression (Zurzuvae) and historically in epilepsy. Its GABAA receptor modulator franchise directly competes with Saniona's SAN2219 and SAN2668 programs in CNS indications.
  • Praxis Precision Medicines: Praxis Precision Medicines is a clinical-stage company developing therapies for CNS disorders including epilepsy and rare pediatric neurological conditions. Its focus on treatment-resistant epilepsies and rare CNS indications directly overlaps Saniona's SAN2668 and SAN2219 programs.

Emerging players

  • Longboard Pharmaceuticals: Longboard Pharmaceuticals is a clinical-stage company developing CNS therapies, including a 5-HT2C receptor agonist for rare epilepsies. Its smaller scale and CNS focus make it an emerging comparable to Saniona's pediatric epilepsy strategy.
  • Engage Therapeutics: Engage Therapeutics (acquired by UCB in 2020) developed a Staccato alprazolam therapy for acute repetitive seizures — directly overlapping with Saniona's SAN2219 program. As a recently validated target in acute seizure treatment, it represents an emerging comparable for Saniona's acute repetitive seizure strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Saniona social profiles

Digital presence

Saniona compliance and trust

Trust signal

Compliance1 record

Saniona financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Saniona leadership team

Management profile

Number of profiles

Profiles6 records

Saniona subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Saniona funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Saniona M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Saniona

What does Saniona do?

Saniona is a clinical-stage biopharmaceutical company that discovers and develops novel treatments for neurological, psychiatric, metabolic, and inflammatory diseases by leveraging a proprietary ion channel drug discovery platform with a library of more than 20,000 proprietary molecules. Its pipeline includes clinical and preclinical candidates for epilepsy (SAN2668, SAN2219, SAN711, SAN2355), depression (SAN2465), inflammatory bowel disease (SAN903), and obesity-related rare disorders (Tesofensin, Tesomet), with most late-stage and commercial rights out-licensed to pharmaceutical partners.

Is Saniona a public or private company?

Saniona is a public company. It is classified as public and is currently operating.

When was Saniona founded?

Saniona was founded in 2011. It employs 51 to 100 people.

Where is Saniona based?

Saniona is headquartered in Glostrup, Denmark, in the Europe region.

How does Saniona make money?

Two revenue lines are on record. Licensing and milestone payments are the primary driver. The others are research and development partnerships.

Who are Saniona's main competitors?

Broad incumbents on record are UCB, Jazz Pharmaceuticals and Acadia Pharmaceuticals. Direct peers are Axsome Therapeutics, Marinus Pharmaceuticals, Xenon Pharmaceuticals, Sage Therapeutics and Praxis Precision Medicines. Emerging players are Longboard Pharmaceuticals and Engage Therapeutics.

Does Saniona have an API?

No public API is recorded for Saniona.

What industry is Saniona in?

Saniona's product category is Clinical-stage biopharmaceuticals (ion channel therapeutics). Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 3254.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingSaniona to Host Q3 Investor CallSaniona will host its Q3 investor call on November 26, 2026, at 15:00 CET. Management will present results and a company update, followed by an online Q&A session.MarketScreenerSaniona receives FDA approval to begin Phase 1 study of depression drugSaniona received FDA clearance to begin a Phase 1 study of its depression drug candidate SAN2465. The first participant is expected to receive treatment before the end of 2026, and the study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. The drug aims to achieve antidepressant effects comparable to ketamine and esketamine while enabling home treatment.The future of tradingBioVal™ analysis of Saniona’s SAN2668 gives an rNPV of SEK 2.37 billionBioStock's BioVal analysis values Saniona's SAN2668 drug candidate for developmental epileptic encephalopathies at a risk-adjusted net present value of SEK 2.37 billion. The base case assumes a 12% probability of marketing approval, with peak sales of SEK 19.37 billion in 2042. The analysis is for the stand-alone project, not the company's overall portfolio.TradingViewBioVal™ analysis of Saniona’s SAN2668 gives an rNPV of SEK 2.37 billionBioStock's BioVal analysis values Saniona's SAN2668 drug candidate for developmental epileptic encephalopathies at a risk-adjusted net present value of SEK 2.37 billion. The base case assumes a 12% probability of marketing approval, with peak sales of SEK 19.37 billion in 2042. The analysis is for the drug alone, not the company.MarketScreenerSaniona submits drug application to FDASaniona submitted an IND application to the FDA for its drug candidate SAN2465 to treat severe depression. The company expects to initiate a Phase 1 study before the end of 2026, subject to FDA clearance, to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.MarketScreenerSaniona completes toxicology and CMC for SAN2465, IND filing expected in OctoberSaniona completed toxicology and CMC for SAN2465 and expects to file an IND with the US FDA before October 2026. The drug targets GABA-A alpha5 receptors for major depressive disorder, with preclinical data showing rapid effects comparable to ketamine. Esketamine sales of $1.7bn in 2025 underscore demand for fast-acting alternatives.AffarsvarldenSaniona minskar omsättning – ökar förlustSaniona reported reduced revenue and higher operating loss in the second quarter of 2026, with net revenue falling 51.6 percent to 4.5 million kronor and operating loss reaching 60.3 million kronor. Cash flow from operations was -47.2 million kronor, while liquid assets stood at 486.3 million kronor. Management said SAN2668 and SAN2465 are prioritized, both expected to start clinical phase 1 studies around the 2026 year-end.Longevity.TechnologyAstronauTx secures exclusive global rights to Saniona’s sleep-based neurological drug candidateAstronauTx has exercised its option to secure exclusive global rights to develop and commercialize the sleep-based neurological drug candidate ATX0926 from Saniona. In exchange, AstronauTx issued Series A shares valued at US$5 million to Saniona, which is also eligible for up to US$172 million in milestone payments and tiered royalties. The drug candidate, developed through a collaboration combining both companies' platforms, is expected to enter IND-enabling studies shortly.The Pharma LetterAstronauTx exercises option on Saniona-partnered Alzheimer's candidateSaniona's UK partner AstronauTx has exercised an option to acquire exclusive worldwide rights to therapeutic candidates from their ion channel collaboration focused on Alzheimer's disease, signed in July 2023. As consideration, AstronauTx will issue Saniona with series A shares worth $5 million, with additional milestone payments of up to $172 million. The deal covers rights to research, develop, manufacture, and commercialize any therapeutic candidates emerging from the partnership.MarketScreenerAstronauTx exercises option in Saniona collaborationAstronauTx exercises an option in a collaboration with Saniona AB, a Swedish biotechnology firm working on ion channel targeting therapeutics. Saniona's projects include treatments for major depressive disorder, schizophrenia, Alzheimer's, pain, and inflammatory bowel disease.